Coya Therapeutics (COYA) Common Equity (2021 - 2026)

Coya Therapeutics has disclosed Common Equity across 6 years of filings, most recently posting $43.3 million for Q2 2026.

• In Q2 2026, Common Equity rose 52.86% year-over-year to $43.3 million; the TTM figure through Jun 2026 stood at $43.3 million (up 52.86% YoY), while the FY2025 annual figure was $43.0 million, up 8.72% from the prior year.
• Common Equity came in at $43.3 million for Q2 2026 at Coya Therapeutics, down from $49.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $49.0 million in Q1 2026 to a low of -$8.4 million in Q4 2022.
• Average Common Equity over 5 years is $23.6 million, with a median of $30.2 million recorded in 2024.
• Year-over-year, Common Equity plunged 330.36% in 2022 and soared 1042.04% in 2023.
• Over 5 years, Common Equity stood at -$8.4 million in 2022, then jumped by 524.56% to $35.6 million in 2023, then gained by 11.06% to $39.6 million in 2024, then gained by 8.72% to $43.0 million in 2025, then climbed by 0.58% to $43.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $43.3 million in Q2 2026, $49.0 million in Q1 2026, and $43.0 million in Q4 2025.